Last reviewed · How we verify
Avandia
At a glance
| Generic name | Avandia |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
- Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies (PHASE2)
- Dietary Fatty Acids As Complementary Therapy in Type 2 Diabetes Mellitus (PHASE1)
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh (PHASE4)
- Rosiglitazone Adjunctive Therapy for Severe Malaria in Children (NA)
- BIIB014 Effects on the Pharmacokinetics (PK) of Rosiglitazone, Warfarin, and Midazolam (PHASE1)
- Rosiglitazone in Treating Patients With Liposarcoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Avandia CI brief — competitive landscape report
- Avandia updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI